How Are Authorized Representative Responsibilities Defined for Overseas Registration of Medical Dressings?

Key Summary

During overseas registration of medical dressings, the allocation of responsibilities with the authorized representative directly determines the ownership of the registration certificate, post-market compliance, and the efficiency of change management. Companies should first confirm whether the target country regulates the dressing as a medical device, then determine the registration pathway based on risk classification—whether self-declaration, registration certification, or pre-market approval. Product classification depends on factors such as the type of wound contact, sterility, and whether the product contains drugs. Different categories impose different obligations on local agents and authorized representatives. Preparation should include technical documentation, performance verification, risk management reports, clinical evaluation or clinical evidence, labels and instructions for use, quality system certificates, as well as the authorization letter and delegation agreement.

Common risks include mistakenly treating the authorized representative as a distributor, granting control of the certificate to an agent without agreeing on change, renewal, and termination clauses, or directly submitting CE or FDA files without localizing them as required by GHWP member states. Companies should first assess the reusability of NMPA, CE, FDA, ISO 13485, or MDSAP documentation, then supplement country-specific documents, clearly defining the authorized representative's responsibilities in notifications, vigilance, recalls, and adverse event reporting. For multi-country registrations, a unified core technical documentation library should be established, with a country-specific gap list, to avoid redundant preparation and correction requests. Ultimately, the division of authorized representative responsibilities must be written into both commercial contracts and technical agreements, ensuring clear registration ownership, controllable changes, and post-market obligations assigned to specific roles.

This article is compiled based on the AIMEILI registration practice database, the medical device international registration knowledge base, and public regulatory information. Specific projects should be based on the latest requirements of the target country's regulatory authority and the product's technical documentation.

Frequently Asked Questions

1. Applicable Scenarios and Core Issues

When medical dressing companies plan to enter overseas markets, the first challenge is determining the division of responsibilities between the registration owner and the agent. Many companies assume that simply finding a local company to serve as the authorized representative means all registration procedures can be handed over, and the company only needs to ship products. This misconception can lead to systemic problems such as unclear certificate ownership, blocked changes, and failed renewals.

The core of authorized representative responsibility is defining who represents the manufacturer in regulatory communications with authorities, who holds the registration certificate, and who is responsible for post-market surveillance and vigilance reporting. Different countries have different definitions: the EU Authorized Representative, the UK Responsible Person, the Saudi Local Agent, and local representatives in Southeast Asian countries have varying roles, but all share the obligation to assume certain statutory duties of the manufacturer in the target market.

Medical dressings cover a wide range—from ordinary adhesive bandages, sterile gauze, and transparent film dressings to silver-containing dressings, hydrocolloid dressings, and alginate dressings—with a broad span of risk classes. Companies must first determine whether the product falls under the medical device regulatory scope in the target country before discussing authorized representatives and registration pathways. If the product is a simple non-sterile adhesive bandage, some countries may manage it as a general commodity, not requiring an authorized representative; however, sterile dressings or those intended for chronic wounds are usually classified as Class I, Class II, or even Class III medical devices.

Therefore, this article addresses companies' actual decision-making needs, outlining registration assessment logic, documentation, evidence chains, common errors, and preparation checklists to help companies establish clear responsibility boundaries with overseas authorized representatives.

2. Registration Assessment Logic

Step 1: Determine whether the product falls under the target country's medical device regulatory scope. Companies should review the target country's medical device definition, classification rules, and exemption lists. For example, the U.S. FDA classifies most medical dressings as Class I or Class II; sterile dressings are Class II and require a 510(k). Under the EU MDR, most dressings are Class I or Class IIa. GHWP member states each have their own classification frameworks, but most reference the principles of the Global Harmonization Working Group.

Step 2: Determine the risk class and registration pathway. The same dressing may be assigned different classes in different countries, directly affecting whether clinical evaluation is required, whether a quality management system audit is mandatory, and whether local representation is needed for the registration application. Companies cannot directly apply Chinese or CE classifications to all countries.

Step 3: Assess the reusability of existing documentation. Existing NMPA registration certificates, CE certificates, FDA 510(k) or premarket approvals, ISO 13485 certificates, and MDSAP certificates can all serve as a basis for technical documentation. However, each country requires locally translated labels, local agent information, and test reports conforming to local standards.

Step 4: Define the responsibility boundaries of the local agent and authorized representative. Companies need to distinguish between the “registration applicant entity” and the “local legal representative.” Most countries require a local entity to submit the application, but the manufacturer remains the legal liability holder. The authorized representative is typically responsible for receiving regulatory notifications, maintaining technical files, participating in adverse event reporting, and recall communication. Companies should include the scope of authorization, signing authority, and document retention obligations in the agreement.

Step 5: Establish a post-market maintenance mechanism. Successful registration does not end responsibilities. The authorized representative must assist in updating registration information, handling changes, applying for renewals, and responding to inspections. Companies should hold quarterly compliance meetings with the authorized representative to track regulatory changes and avoid registration suspension due to outdated contact information or non-compliant agents.

3. Documentation and Evidence

The documentation package for overseas registration of medical dressings typically includes product description, intended use, composition and materials, manufacturing process, sterilization validation, biological evaluation, performance testing, stability data, and label/IFU samples. These items must be formatted according to the target country's requirements, not simply translated without adjustment.

The risk management report is core evidence. Companies should establish risk management documentation based on ISO 14971 and supplement usage scenarios and risk control measures specific to the target country's medical practice. For example, silver-containing dressings may be considered antibacterial products in some countries, requiring additional safety data; alginate dressings need to consider absorption capacity and residue risks.

Clinical evaluation or clinical evidence depends on the risk class. Low-risk, non-sterile dressings may be supported by literature review and equivalence comparison; high-risk or newly claimed dressings may require local clinical trials. Companies should consult the target country's regulatory authority or authorized representative early to confirm the acceptability of clinical evidence.

Labels and instructions for use must be localized. Beyond translation, they must comply with the target country's requirements for symbols, units, warnings, and Unique Device Identification (UDI). The authorized representative's name and address should be formatted according to local requirements, not simply printed with the foreign agent's English address.

Quality system documentation is also mandatory evidence. An ISO 13485 certificate covers most markets; if the target country accepts MDSAP, companies may reduce duplicate audits. However, some countries still require on-site audits or factory inspections, so early scheduling is advised.

Finally, the authorization letter and delegation agreement are direct evidence of responsibility allocation. The agreement should specify the authorized representative's scope of services, duration, fees, termination conditions, certificate change procedures, adverse event reporting timelines, and data protection responsibilities.

4. Common Errors

• Treating the authorized representative as a distributor or importer without a separate regulatory authorization agreement, leading to blurred responsibility boundaries.
• Ignoring the qualifications and change capability of the authorized representative. Some countries require the local agent to be a registered entity with compliance personnel; companies fail to verify this.
• Directly submitting CE or FDA technical files to GHWP member states without localization, causing deficiency letters and delays.
• Failing to contractually stipulate control of the registration certificate. When later changing authorized representatives, the original agent may refuse to transfer the certificate, resulting in registration lapse.
• Neglecting post-market obligations, assuming the authorized representative is fully responsible for adverse event reporting without establishing internal vigilance processes.
• Misclassifying products, such as registering drug-containing or sterile dressings as ordinary bandages, creating major compliance risks.

5. Company Preparation Checklist

• List target countries and confirm, one by one, the regulatory scope, device classification, and registration pathway, creating a comparison table.
• Establish a product technical documentation library covering design, materials, processes, sterilization, performance, biocompatibility, and stability data.
• Obtain or update ISO 13485 certification and assess whether MDSAP certification is needed.
• Prepare or update an ISO 14971-compliant risk management report, including target-country usage scenarios.
• Complete localized translation of labels and IFU, and verify UDI, symbols, and agent information.
• Screen candidate authorized representatives, requesting qualification evidence, service case references, and adverse event handling procedures.
• Sign clear authorization agreements that define responsibility allocation, fee structures, and change/termination clauses.
• Develop a post-market surveillance plan, designating an internal vigilance officer and establishing a communication mechanism with the authorized representative.

6. AIMEILI Insights

Companies often mistakenly believe that having more authorized representatives is better, or that any local trading company can handle registration. In fact, the authorized representative is a regulatory role that must have the ability to communicate with regulatory authorities, understand technical documentation, and handle vigilance events. Companies should elevate the selection of an authorized representative to a strategic level.

Early in the project, companies should conduct a regulatory gap analysis for the target country rather than rushing to sign an agent. First clarify the classification, registration pathway, and clinical evidence requirements, then prepare documentation based on the gaps. This approach avoids multiple deficiency rounds.

In terms of documentation reuse, NMPA registration data, CE technical files, and FDA 510(k) files can all serve as a basis, but must be localized. Risk management, clinical evaluation, and labels/IFU cannot simply be translated. Performance testing and sterilization validation are often reusable, but verify whether the test standards are accepted by the target country.

Local agents, certificate control, changes, and renewals are long-term risk points. Companies should include in the contract the following: the registration certificate belongs to the manufacturer, with the authorized representative serving only as an agent; all change applications require the manufacturer's written consent; upon termination of the authorized representative, there is an obligation to assist in transferring the certificate; and renewals are led by the manufacturer, with the agent's support.

For multi-country registrations, companies should build a core documentation library and a country-specific difference matrix. The same dressing may have different classifications, agent requirements, language requirements, and clinical evidence thresholds in different countries. Managing all countries' progress and requirements with a single master list significantly reduces redundant work and deficiency risks.

7. Common Follow-up Questions

What is the difference between an authorized representative and a local distributor? An authorized representative is a regulatory role that represents the manufacturer in the target country for communications with authorities and bears obligations such as document retention, adverse event notification, and recall assistance. A distributor is a commercial role responsible for sales and logistics, with no registration responsibilities. Companies must execute separate agreements and cannot conflate the two.

How is the registration certificate handled when changing authorized representatives? Most countries allow changing the authorized representative, but a change application must be submitted to the regulatory authority, including a new authorization letter, a termination letter from the original authorized representative, and certificate transfer documents confirmed by both parties. Companies should contractually stipulate the original agent's cooperation obligations in advance; otherwise, the registration may lapse.

Is local clinical evaluation always required for medical dressings in GHWP member states? Not necessarily. Most GHWP member states accept risk management documentation and equivalence comparisons, but sterile dressings, dressings with active ingredients, or new materials being introduced for the first time may require local clinical data. Companies should first review the target country's clinical evaluation guidelines or consult the regulatory authority through the authorized representative for confirmation.

Continue Reading

Previous: How is the ISO 13485 certificate used for overseas registration of medical dressings?
Next: Why does the registration cycle for medical dressings extend?

Recommended reading: How are authorized representative responsibilities defined for overseas registration of disinfection and sterilization equipment? How are authorized representative responsibilities defined for overseas registration of rehabilitation equipment? How are authorized representative responsibilities defined for overseas registration of imaging equipment? How are authorized representative responsibilities defined for overseas registration of home medical devices? How are authorized representative responsibilities defined for overseas registration of IVD products? How do you localize labels and instructions for medical dressings?
Return to FAQ Center | News | Contact AIMEILI

Content Review and Applicability

Author: AIMEILI Regulatory Editorial Department
Professional Review: AIMEILI Medical Device International Registration Project Team
Source Principles: Priority is given to official regulatory authorities, international organizations, standard organizations, and public regulatory materials; industry media and project experience are used only as supplementary references.
Applicability: This article is intended for preliminary understanding, documentation preparation, and project planning. It does not replace the official requirements of target country regulatory authorities, testing conclusions, or legal opinions.